{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T02:57:34Z","timestamp":1649213854546},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s11883-008-0022-2","type":"journal-article","created":{"date-parts":[[2008,4,5]],"date-time":"2008-04-05T08:27:10Z","timestamp":1207384030000},"page":"149-157","source":"Crossref","is-referenced-by-count":1,"title":["Aspirin resistance in atherosclerosis"],"prefix":"10.1007","volume":"10","author":[{"given":"Price","family":"Blair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane E.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,6]]},"reference":[{"key":"22_CR1","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIRCULATIONAHA.106.179918","volume":"115","author":"W. Rosamond","year":"2007","unstructured":"Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69\u2013e171.","journal-title":"Circulation"},{"key":"22_CR2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","volume":"101","author":"E.H. Awtry","year":"2000","unstructured":"Awtry EH, Loscalzo J: Aspirin. Circulation 2000, 101:1206\u20131218.","journal-title":"Circulation"},{"key":"22_CR3","first-page":"38","volume":"75","author":"L. Craven","year":"1953","unstructured":"Craven L: Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Miss Valley Med J 1953, 75:38\u201344.","journal-title":"Miss Valley Med J"},{"key":"22_CR4","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacc.2004.08.070","volume":"46","author":"P.J. Mason","year":"2005","unstructured":"Mason PJ, Jacobs AK, Freedman JE: Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005, 46:986\u2013993.","journal-title":"J Am Coll Cardiol"},{"key":"22_CR5","doi-asserted-by":"crossref","unstructured":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"22_CR6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S. Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494\u2013502.","journal-title":"N Engl J Med"},{"key":"22_CR7","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"S.R. Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411\u20132420.","journal-title":"JAMA"},{"key":"22_CR8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0049-3848(93)90164-J","volume":"71","author":"K.H. Grotemeyer","year":"1993","unstructured":"Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993, 71:397\u2013403.","journal-title":"Thromb Res"},{"key":"22_CR9","first-page":"1385","volume":"16","author":"M.R. Buchanan","year":"2000","unstructured":"Buchanan MR, Schwartz L, Bourassa M, et al.: Results of the BRAT study-a pilot study investigating the possible significance of ASA non-responsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000, 16:1385\u20131390.","journal-title":"Can J Cardiol"},{"key":"22_CR10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0049-3848(02)00405-X","volume":"108","author":"K. Andersen","year":"2002","unstructured":"Andersen K, Hurlen M, Arnesen H, Seljeflot I: Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002, 108:37\u201342.","journal-title":"Thromb Res"},{"key":"22_CR11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","volume":"105","author":"J.W. Eikelboom","year":"2002","unstructured":"Eikelboom JW, Hirsh J, Weitz JI, et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650\u20131655.","journal-title":"Circulation"},{"key":"22_CR12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","volume":"41","author":"P.A. Gum","year":"2003","unstructured":"Gum PA, Kottke-Marchant K, Welsh PA, et al.: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961\u2013965.","journal-title":"J Am Coll Cardiol"},{"key":"22_CR13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ahj.2003.07.011","volume":"147","author":"G. Cotter","year":"2004","unstructured":"Cotter G, Shemesh E, Zehavi M, et al.: Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004, 147:293\u2013300.","journal-title":"Am Heart J"},{"key":"22_CR14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11239-006-8952-4","volume":"22","author":"B. Pamukcu","year":"2006","unstructured":"Pamukcu B, Oflaz H, Oncul A, et al.: The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 2006, 22:103\u2013110.","journal-title":"J Thromb Thrombolysis"},{"key":"22_CR15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejim.2006.01.006","volume":"17","author":"D. Stejskal","year":"2006","unstructured":"Stejskal D, Vaclavik J, Lacnak B, Proskova J: Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006, 17:349\u2013354.","journal-title":"Eur J Intern Med"},{"key":"22_CR16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.amjmed.2006.10.021","volume":"120","author":"W.H. Chen","year":"2007","unstructured":"Chen WH, Cheng X, Lee PY, et al.: Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007, 120:631\u2013635.","journal-title":"Am J Med"},{"key":"22_CR17","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","volume":"119","author":"C. Patrono","year":"2001","unstructured":"Patrono C, Coller B, Dalen JE, et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001, 119:39S\u201363S.","journal-title":"Chest"},{"key":"22_CR18","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","volume":"99","author":"B. Rocca","year":"2002","unstructured":"Rocca B, Secchiero P, Ciabattoni G, et al.: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002, 99:7634\u20137639.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"22_CR19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1160\/TH04-02-0127","volume":"92","author":"A.O. Maree","year":"2004","unstructured":"Maree AO, Fitzgerald DJ: Aspirin and coronary artery disease. Thromb Haemost 2004, 92:1175\u20131181.","journal-title":"Thromb Haemost"},{"key":"22_CR20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","volume":"69","author":"P. Patrignani","year":"1982","unstructured":"Patrignani P, Filabozzi P, Patrono C: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982, 69:1366\u20131372.","journal-title":"J Clin Invest"},{"key":"22_CR21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.thromres.2006.11.012","volume":"120","author":"P. Harrison","year":"2007","unstructured":"Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD: Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007, 120:323\u2013336.","journal-title":"Thromb Res"},{"key":"22_CR22","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1161\/CIRCULATIONAHA.107.699165","volume":"115","author":"J.E. Freedman","year":"2007","unstructured":"Freedman JE: Heritability, platelet function, and aspirin: a link established but cause unknown. Circulation 2007, 115:2468\u20132470.","journal-title":"Circulation"},{"key":"22_CR23","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1161\/01.RES.0000074030.98009.FF","volume":"92","author":"J.E. Freedman","year":"2003","unstructured":"Freedman JE: CD40-CD40L and platelet function: beyond hemostasis. Circ Res 2003, 92:944\u2013946.","journal-title":"Circ Res"},{"key":"22_CR24","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/eurheartj\/ehm232","volume":"28","author":"M. Cattaneo","year":"2007","unstructured":"Cattaneo M: Laboratory detection of \u2018aspirin resistance\u2019: what test should we use (if any)? Eur Heart J 2007, 28:1673\u20131675.","journal-title":"Eur Heart J"},{"key":"22_CR25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0021-9150(78)90162-4","volume":"31","author":"J. Mehta","year":"1978","unstructured":"Mehta J, Mehta P, Burger C, Pepine CJ: Platelet aggregation studies in coronary artery disease. Part 4. Effect of aspirin. Atherosclerosis 1978, 31:169\u2013175.","journal-title":"Atherosclerosis"},{"key":"22_CR26","doi-asserted-by":"crossref","first-page":"11N","DOI":"10.1016\/j.amjcard.2006.09.009","volume":"98","author":"X. Cheng","year":"2006","unstructured":"Cheng X, Chen WH, Simon DI: Aspirin resistance or variable response or both? Am J Cardiol 2006, 98:11N\u201317N.","journal-title":"Am J Cardiol"},{"key":"22_CR27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2006.10.040","volume":"153","author":"M.M. Hovens","year":"2007","unstructured":"Hovens MM, Snoep JD, Eikenboom JC, et al.: Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007, 153:175\u2013181.","journal-title":"Am Heart J"},{"key":"22_CR28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","volume":"167","author":"J.D. Snoep","year":"2007","unstructured":"Snoep JD, Hovens MM, Eikenboom JC, et al.: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007, 167:1593\u20131599.","journal-title":"Arch Intern Med"},{"key":"22_CR29","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2006-01-010645","volume":"109","author":"A. Undas","year":"2007","unstructured":"Undas A, Brummel-Ziedins KE, Mann KG: Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007, 109:2285\u20132292.","journal-title":"Blood"},{"key":"22_CR30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjcard.2004.12.038","volume":"95","author":"K.A. Schwartz","year":"2005","unstructured":"Schwartz KA, Schwartz DE, Ghosheh K, et al.: Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005, 95:973\u2013975.","journal-title":"Am J Cardiol"},{"key":"22_CR31","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.667584","volume":"115","author":"N. Faraday","year":"2007","unstructured":"Faraday N, Yanek LR, Mathias R, et al.: Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007, 115:2490\u20132496.","journal-title":"Circulation"},{"key":"22_CR32","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","volume":"108","author":"T. Kurth","year":"2003","unstructured":"Kurth T, Glynn RJ, Walker AM, et al.: Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003, 108:1191\u20131195.","journal-title":"Circulation"},{"key":"22_CR33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0002-9149(99)00049-1","volume":"83","author":"J.H. Alexander","year":"1999","unstructured":"Alexander JH, Harrington RA, Tuttle RH, et al.: Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb\/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999, 83:1147\u20131151.","journal-title":"Am J Cardiol"},{"key":"22_CR34","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacc.2003.08.062","volume":"43","author":"F.M. Pulcinelli","year":"2004","unstructured":"Pulcinelli FM, Pignatelli P, Celestini A, et al.: Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004, 43:979\u2013984.","journal-title":"J Am Coll Cardiol"},{"key":"22_CR35","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","volume":"37","author":"D. Cox","year":"2006","unstructured":"Cox D, Maree AO, Dooley M, et al.: Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006, 37:2153\u20132158.","journal-title":"Stroke"},{"key":"22_CR36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jacc.2005.06.058","volume":"46","author":"A.O. Maree","year":"2005","unstructured":"Maree AO, Curtin RJ, Dooley M, et al.: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005, 46:1258\u20131263.","journal-title":"J Am Coll Cardiol"},{"key":"22_CR37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.ijo.0802312","volume":"27","author":"M. Tamminen","year":"2003","unstructured":"Tamminen M, Lassila R, Westerbacka J, et al.: Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003, 27:907\u2013911.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"22_CR38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1538-7836.2007.02387.x","volume":"5","author":"S. Guthikonda","year":"2007","unstructured":"Guthikonda S, Lev EI, Patel R, et al.: Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007, 5:490\u2013496.","journal-title":"J Thromb Haemost"},{"key":"22_CR39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.ATV.0000104005.92603.f2","volume":"24","author":"F. Cipollone","year":"2004","unstructured":"Cipollone F, Rocca B, Patrono C: Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004, 24:246\u2013255.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"22_CR40","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1538-7836.2007.02378.x","volume":"5","author":"A. Modica","year":"2007","unstructured":"Modica A, Karlsson F, Mooe T: Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 2007, 5:507\u2013511.","journal-title":"J Thromb Haemost"},{"key":"22_CR41","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1161\/CIRCULATIONAHA.106.635847","volume":"113","author":"J.E. Freedman","year":"2006","unstructured":"Freedman JE: The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation 2006, 113:2865\u20132867.","journal-title":"Circulation"},{"key":"22_CR42","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1160\/TH07-01-0047","volume":"97","author":"A. Undas","year":"2007","unstructured":"Undas A, Placzkiewicz-Jankowska E, Zielinski L, Tracz W: Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. Thromb Haemost 2007, 97:1056\u20131058.","journal-title":"Thromb Haemost"},{"key":"22_CR43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0049-3848(00)00297-8","volume":"99","author":"M. Homoncik","year":"2000","unstructured":"Homoncik M, Jilma B, Eichelberger B, Panzer S: Inhibitory activity of aspirin on von Willebrand factor-induced platelet aggregation. Thromb Res 2000, 99:461\u2013466.","journal-title":"Thromb Res"},{"key":"22_CR44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.thromres.2006.05.003","volume":"119","author":"W. Kuliczkowski","year":"2007","unstructured":"Kuliczkowski W, Kobusiak-Prokopowicz M, Prajs I, et al.: Aspirin failure course during exercise and its connection with soluble CD40L. Thromb Res 2007, 119:679\u2013686.","journal-title":"Thromb Res"},{"key":"22_CR45","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","volume":"113","author":"A.L. Frelinger 3rd","year":"2006","unstructured":"Frelinger AL 3rd, Furman MI, Linden MD, et al.: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006, 113:2888\u20132896.","journal-title":"Circulation"},{"key":"22_CR46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.thromres.2006.04.004","volume":"119","author":"S. Takahashi","year":"2007","unstructured":"Takahashi S, Ushida M, Komine R, et al.: Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 2007, 119:517\u2013524.","journal-title":"Thromb Res"},{"key":"22_CR47","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/01.CIR.103.25.3051","volume":"103","author":"C.J. O\u2019Donnell","year":"2001","unstructured":"O\u2019Donnell CJ, Larson MG, Feng D, et al.: Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001, 103:3051\u20133056.","journal-title":"Circulation"},{"key":"22_CR48","doi-asserted-by":"crossref","unstructured":"Takahashi S, Ushida M, Komine R, et al.: Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2007, [Epub ahead of print].","DOI":"10.1016\/j.thromres.2007.05.017"},{"key":"22_CR49","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/j.1538-7836.2005.01555.x","volume":"3","author":"A.O. Maree","year":"2005","unstructured":"Maree AO, Curtin RJ, Chubb A, et al.: Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005, 3:2340\u20132345.","journal-title":"J Thromb Haemost"},{"key":"22_CR50","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","volume":"109","author":"S. Matetzky","year":"2004","unstructured":"Matetzky S, Shenkman B, Guetta V, et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171\u20133175.","journal-title":"Circulation"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-008-0022-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-008-0022-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-008-0022-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:35:33Z","timestamp":1559432133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-008-0022-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["22"],"URL":"https:\/\/doi.org\/10.1007\/s11883-008-0022-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}